Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

Lancora 5 mg tablet

Canada Type III Ongoing · initiated 2026-06-16

Product quality. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health co…

Par Health USA, LLC

US Class II Ongoing · initiated 2026-06-12

Crystallization; identified as Buprenorphine free base

Boehringer Ingelheim Pharmaceuticals, Inc.

US Class II Ongoing · initiated 2026-06-12

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a dif…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

CareFusion 213, LLC

US Class II Ongoing · initiated 2026-06-11

Lack of assurance of sterility: Unsterilized ChloraPrep & PurPrep Applicators, intended for further processing and sterilization were instead distributed to cus…

BioMed Laboratories, LLC.

US Class II Ongoing · initiated 2026-06-11

Failed Impurities/Degradation Specifications; Formaldehyde levels exceeded specification.

ACCORD BIOPHARMA INC

US Class II Ongoing · initiated 2026-06-10

Lack of assurance of Sterility:

Nicotine Pouch

Canada Type II Ongoing · initiated 2026-06-10

Unauthorized product. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any heal…

Asclemed USA Inc.

US Class II Ongoing · initiated 2026-06-08

Lack of Assurance of Sterility

ACCORD HEALTHCARE, INC.

US Class II Ongoing · initiated 2026-06-08

Subpotent Drug

Asclemed USA Inc.

US Class II Ongoing · initiated 2026-06-08

Lack of Assurance of Sterility

Sodium chloride injection; Sodium chloride Irrigation; (20 mmol/L) Potassium chloride in 5% Dextrose and 0.9% Sodium chloride injection; Lactated Ringer's injection

Canada Type III Ongoing · initiated 2026-06-08

Packaging. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns…

PMS-Fluconazole 50 mg tablets

Canada Type III Ongoing · initiated 2026-06-08

Packaging. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns…

ONESOURCE SPECIALTY PHARMA LIMITED

US Class II Ongoing · initiated 2026-06-07

Failed Impurities/Degradation Specifications

Inventia Healthcare Limited

US Class II Ongoing · initiated 2026-06-05

Failed Dissolution Specifications

Haleon US Holdings LLC

US Class I Ongoing · initiated 2026-06-04

Chemical Contamination: contamination with a diluted propylene glycol-based coolant from a machine leakage during the packaging process.

Breckenridge Pharmaceutical, Inc.

US Class II Ongoing · initiated 2026-06-04

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit